2-(2-naphthalen-2-yl-ethoxy)-acetamidine hydrochloride | 958361-36-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(2-naphthalen-2-yl-ethoxy)-acetamidine hydrochloride
• 英文别名: 2-(2-naphthalen-2-ylethoxy)ethanimidamide;hydrochloride
• CAS: 958361-36-9
• 化学式: C₁₄H₁₆N₂O*ClH
• 分子量: 264.755
• InChiKey: OQLNHERTUULKJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.76
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  59.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-naphthalen-2-yl-ethoxy)-acetamidine hydrochloride 、 2-氯吡嗪-3-羧酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 3-Chloro-pyrazine-2-carboxylic acid[1-imino-2-(2-naphthalen-2-yl-ethoxy)-ethyl]-amide
  参考文献：
  名称：

  NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES

  摘要：

  这项发明涉及式(I)的新颖的氮杂吡啶嘧啶酮衍生物： 其中R1、R2、R3、R4、R5、X1、X2、X3、Y、Z、m和n如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物是HM74A激动剂，可用于治疗或预防受HM74A激动剂调节的疾病。

  公开号：

  US20080234277A1

文献信息

• Novel pyridopyprimidinone derivatives which are HM74A agonists
  申请人：Conte Aurelia

  公开号：US20070275987A1

  公开（公告）日：2007-11-29

  The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R 1 to R 8 , X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.

  这项发明涉及式(I)的新型吡啶吡嘧啶酮衍生物：其中R1至R8、X、Y、m和n如描述和索赔中所定义。本发明的化合物是HM74A激动剂，与烟酸相比具有改进的性能，并可用于治疗和/或预防与HM74A相关的疾病，如脂质代谢异常、动脉粥样硬化、糖尿病、代谢综合征和其他与HM74A相关的疾病。
• Pyridopyrimidinone derivatives which are HM74A agonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07572801B2

  公开（公告）日：2009-08-11

  The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.

  本发明涉及公式（I）的新型吡啶吡嗪酮衍生物：其中R1至R8、X、Y、m和n如说明书和权利要求所定义。本发明的化合物是HM74A激动剂，与烟酸相比具有改善的性质，可用于治疗和/或预防与HM74A相关的疾病，如血脂异常、动脉硬化、糖尿病、代谢综合征和其他相关疾病。
• Aza-pyridopyrimidinone derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07928106B2

  公开（公告）日：2011-04-19

  The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, X1, X2, X3, Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used in treating or preventing diseases which are modulated by HM74A agonists.

  本发明涉及式(I)的新型氮杂吡啶嘧啶酮衍生物：其中R1、R2、R3、R4、R5、X1、X2、X3、Y、Z、m和n如说明书和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物是HM74A激动剂，可用于治疗或预防受HM74A激动剂调节的疾病。
• PYRIDOPYRIMIDINONE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2029601B1

  公开（公告）日：2010-06-02
• AZA-PYRIDOPYRIMIDINONE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2139895A1

  公开（公告）日：2010-01-06